secwatch.observer — SEC 8-K summary
======================================

Issuer:     Artiva Biotherapeutics, Inc. (ARTV)
CIK:        0001817241
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001193125-25-275902
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artiva reports AlloNK shows deep B-cell depletion in 32 autoimmune patients; FDA interaction planned 1H 2026
--------------------------------------------------------------------------------

- 32 patients dosed with AlloNK + anti-CD20 mAb as outpatients at community rheumatology sites; no CRS, ICANS or GvHD.
- No Grade 3+ AlloNK-related TEAEs, no discontinuations; only one hospitalization (unrelated skin infection).
- All 23 analyzed patients had undetectable peripheral CD19+ B-cells by Day 13; high-sensitivity assay confirms depletion.
- B-cell depletion depth comparable to CD19-auto-CAR-T, greater than rituximab alone per published studies.
- Plans to share initial RA response data from >15 patients and align with FDA on pivotal trial design in 1H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817241/000119312525275902/0001193125-25-275902-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817241/000119312525275902/artv-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-275902

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer